Sheldon Koenig, Esperion CEO
October 18, 2021 10:38 AM EDTUpdated 10:57 AM
People
Pharma

Es­pe­ri­on gets out the bud­get ax, chop­ping 170 staffers as its big drug launch sput­ters

Nicole DeFeudis

Editor

Es­pe­ri­on’s ex­ec­u­tive team spent years in­sist­ing that they had found the sweet spot in the mar­ket for their cho­les­terol drug. But that strat­e­gy has soured …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

Rev­o­lu­tion Med­i­ci­nes' KRAS drug shows po­ten­tial in ear­ly cut of lung can­cer da­ta

Schol­ar Rock names new CEO, adds biotech vet­er­ans in C-suite re­build

Ex­clu­sive: Can AI re­place an­i­mal test­ing? A new biotech launch­es to find out

France stops Val­neva's chikun­gun­ya vac­cine roll­out in over 65s af­ter safe­ty is­sue

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times